Skip to main content

Security report for biogen.ee

Biogen Estonia OÜ · Healthcare · Estonia

Low risk. 2 critical or high findings in Email security and SSL/TLS.

Security score

77/100

Risk levelLow

0–100, higher is better. How it is calculated

Biogen Estonia OÜ operates as a local branch of the global biotechnology leader Biogen Inc., focusing on innovative treatments for complex neurological, neuropsychiatric, immunological, and rare diseases. The website is professionally designed, localized in Estonian, and provides comprehensive information about the company's mission, disease areas, and career opportunities. The digital infrastructure is built on Adobe Experience Manager, leveraging modern technologies such as jQuery, Google Tag Manager, and Cookiebot for consent management. Security posture is strong with HTTPS enforced and privacy-conscious analytics configuration. However, explicit security policies and incident response contacts are not published, representing an area for improvement. Overall, the website demonstrates a mature digital presence aligned with corporate standards and regulatory compliance.

Scanned

NIS2 and GDPR posture

GDPR outside view
83/ 100 · Low
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

2 findings rated critical or high. Fix these first.

  1. Email security

    SPF, DKIM and DMARC stop others sending email that looks like it comes from your domain, a common route to phishing and invoice fraud.

    • Critical

      No email authentication configured

      Domain is vulnerable to email spoofing

      What to do: Implement SPF, DKIM, and DMARC immediately

  2. SSL/TLS

    TLS encrypts the connection and proves the site is really yours. Weak or expiring certificates trigger browser warnings and put traffic at risk.

    • High

      Weak Protocols Supported

      Server supports weak protocols: TLSv1.1

      What to do: Disable TLS 1.0, TLS 1.1, and all SSL versions

      • CWE-327
      • OWASP A04:2025
      • ASVS V12.1.1

Need hands-on remediation? Email guard@offseq.com

Keep watching biogen.ee

This scan found 20 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. The full timeline opens with your unlock code.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
62
Security headers
95
Email security
60
DNS health
60
Network security
100
GDPR outside view
83
Average
77

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

Biogen Estonia is positioned as a key player in the healthcare biotechnology sector within Estonia, serving a general audience including patients, healthcare professionals, and potential employees. The business model centers on research, development, and commercialization of therapies for neurological and rare diseases. The website reflects a global-local strategy with links to multiple country-specific Biogen sites, indicating a broad partnership ecosystem. The absence of direct contact emails or phone numbers on the homepage suggests a controlled communication channel via contact forms, typical for regulated industries. The company maintains a consistent brand image and leverages social media for outreach. Growth indicators include active career pages and scientific innovation content.

Security posture

The website employs HTTPS with a valid SSL configuration and integrates Cookiebot for GDPR-compliant cookie consent management. Google Analytics is configured with IP anonymization, reflecting privacy-conscious data collection. However, the absence of visible security headers such as Content-Security-Policy or X-Frame-Options reduces defense-in-depth. No published security policy or incident response information limits transparency and readiness perception. No vulnerabilities or exposed sensitive data were detected in the analysis. Overall, the security posture is solid but could be enhanced by publishing security policies, incident response contacts, and implementing additional HTTP security headers.

Recommendations

  1. Publish a dedicated security policy page outlining security practices and compliance.
  2. Add incident response contact information (e.g., security@biogen.ee) to facilitate vulnerability reporting.
  3. Implement and enforce HTTP security headers such as Content-Security-Policy, X-Frame-Options, and X-Content-Type-Options.
  4. Consider publishing a security.txt file to formalize vulnerability disclosure processes.
  5. Enhance accessibility features to improve compliance with WCAG standards.
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
Biogen Estonia OÜ
Description
Biogen on juhtiv ülemaailmne biotehnoloogiaettevõte, mis on teaduse teerajajaks edendades uuendusi keeruliste ja laastavate haiguste raviks. Biogen arendab ravimeetodeid neuroloogia, neuropsühhiaatria, spetsialiseeritud immunoloogia ja haruldaste haiguste valdkonnas ning on jätkuvalt keskendunud oma eesmärgile teenida inimkonda teaduse kaudu, edendades samal ajal tervislikumat, jätkusuutlikumat ja õiglasemat maailma.
Key services
development of treatments in neurology, neuropsychiatry, specialized immunology, rare diseases
Content quality
good
Branding
consistent

Technology

Stack
jQuery 3.6.4, Adobe Helix RUM, Cookiebot, Google Tag Manager, Google Analytics
Frameworks
Adobe Experience Manager (AEM)
Performance
moderate
Mobile
good
Accessibility
basic
SEO
good

Security

Observed score
85/100
Good practices seen
  • HTTPS enforced
  • Cookie consent mechanism implemented
  • IP anonymization enabled for Google Analytics

Analytics and tracking

Services
Google Analytics
Tracking level
moderate
Privacy practices
good

Advertising

Tracking pixels
Cookiebot session tracker
Marketing tools
Cookiebot
Transparency
good

Site quality

Design
good
User experience
good
Content relevance
good
Navigation
good
Professionalism
good
Trustworthiness
high

Key observations

  1. Website is professionally designed and localized for Estonia.
  2. Comprehensive cookie consent mechanism implemented with Cookiebot.
  3. Use of Adobe Experience Manager CMS indicates enterprise-grade platform.
  4. Social media presence is linked to official Biogen profiles.
  5. No direct contact emails or phone numbers found on homepage; contact form available.
  6. No explicit security policy or incident response information published.
  7. No security.txt or vulnerability disclosure page detected.
  8. Google Analytics configured with IP anonymization for GDPR compliance.
  9. No suspicious or malicious content detected.
Technical notes

Notes

The website is built on Adobe Experience Manager, an enterprise-grade CMS, ensuring scalability and content management efficiency. The tech stack includes jQuery 3.6.4, Google Tag Manager, and Cookiebot for analytics and consent management. Performance is moderate with video content and images optimized for responsiveness. SEO is supported by proper meta tags and Open Graph data. Mobile optimization is good, with responsive navigation and images. Some technical debt is indicated by legacy jQuery usage and lack of advanced accessibility features. Overall, the technical infrastructure supports a professional and compliant digital presence with room for modernization.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with biogen.ee. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review biogen.ee.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.